Abbott Laboratories (ABT) to Release Earnings on Thursday

Abbott Laboratories (NYSE:ABT - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, July 17th. Analysts expect the company to announce earnings of $1.25 per share and revenue of $11.01 billion for the quarter. Abbott Laboratories has set its Q2 2025 guidance at 1.230-1.270 EPS and its FY 2025 guidance at 5.050-5.250 EPS.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Stock Performance

NYSE ABT traded down $1.82 during trading hours on Friday, hitting $131.79. The company's stock had a trading volume of 1,811,964 shares, compared to its average volume of 6,138,159. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company's 50 day simple moving average is $133.54 and its two-hundred day simple moving average is $128.86. The company has a market cap of $229.28 billion, a P/E ratio of 17.08, a price-to-earnings-growth ratio of 2.53 and a beta of 0.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. Abbott Laboratories's payout ratio is currently 30.61%.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Barclays boosted their price target on Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a report on Thursday, April 17th. Jefferies Financial Group lifted their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the stock a "hold" rating in a research note on Thursday, April 17th. Raymond James Financial lifted their price objective on Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, April 17th. Stifel Nicolaus lifted their price objective on Abbott Laboratories from $135.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th. Finally, Evercore ISI lifted their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Tuesday. Six equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus price target of $143.11.

Insider Activity at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director owned 34,058 shares in the company, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.46% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC lifted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 51,719 shares of the healthcare product maker's stock after buying an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent reporting period. 75.18% of the stock is owned by institutional investors.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.